Supramolecular cyclodextrin nanocarriers for chemo- and gene therapy towards the effective treatment of drug resistant cancers.
A tumor active targeting β-cyclodextrin based nanocarrier β-NC-OEI-SS-FA was designed by the modification of star shaped cationic derivatives β-NC-OEI with folic acid through a disulfide bond, to co-deliver chemotherapeutic paclitaxel and the Nur77 gene for overcoming Bcl-2 mediated non-pump resistance by an "enemy to friend" strategy for potential drug resistant cancer therapy.
Fujian Provincial Key Laboratory of Innovative Drug Target Research and State Key Laboratory of Cellular Stress Biology, School of Pharmaceutical Sciences, Xiamen University, Xiamen, 361102, P. R. China. wuyl@xmu.edu.cn.
Xiaohong
X
Chen
Ying-Kun
YK
Qiu
Cally
C
Owh
Xian Jun
XJ
Loh
Yun-Long
YL
Wu
D000818:Animals; D003505:Cyclodextrins / Q000737:chemistry*; D016503:Drug Delivery Systems; D019008:Drug Resistance, Neoplasm; D005492:Folic Acid / Q000737:chemistry*; D015316:Genetic Therapy; D006367:HeLa Cells; D056945:Hep G2 Cells; D006801:Humans; D051379:Mice; D015394:Molecular Structure; D053758:Nanoparticles; D009369:Neoplasms / Q000628:therapy*; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1 / Q000235:genetics; D017239:Paclitaxel / Q000008:administration & dosage; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
C000595707:BCL2 protein, human; D003505:Cyclodextrins; D057105:Nuclear Receptor Subfamily 4, Group A, Member 1; D019253:Proto-Oncogene Proteins c-bcl-2; D005492:Folic Acid; D017239:Paclitaxel